Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single versus repeated intracoronary autologous bone marrow-derived mononuclear cell therapy in chronic post-infarction heart failure
2011-000595-33Phase 2Suspended
- Sponsor
- Goethe University Frankfurt
- Start
- Sep 2012
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of T2C001-AMI in heart failure (HF), ischaemic cardiomyopathy (ICM) and myocardial infarction (MI) (2 arms), sponsored by Goethe University Frankfurt. Primary endpoint: 2-year observed mortality. Started Sep 2012; status: suspended.
02
Drugs
T2C001-AMI
03
Conditions
heart failure (HF)ischaemic cardiomyopathy (ICM)myocardial infarction (MI)
Beyond the preview
Go deeper on 2011-000595-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000595-33.